Anthem Biosciences Limited

ANTHEMNotably above fair value

A 6-pillar fundamental profile. Each pillar scored 0–10.

7.0/10 composite
Prism for ANTHEM.NS: composite 7.0 of 10, verdict Notably above fair valuePULSEQUALITYMOATSAFETYGROWTHVALUE10.06.76.59.06.4Below cohort range

Pulse

10.0 · Positive

Analyst revision trend (fallback)

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means more positive near-term tailwinds.

Quality

6.7 · Moderate

Piotroski 5/9, ROCE 26.9%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

6.5 · Moderate

Narrow moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

9.0 · Strong

D/E 0.02, Int cov 66.6x

Safety looks at balance-sheet quality, leverage, and cash generation. Higher means lower financial risk.

Growth

6.4 · Moderate

Rev CAGR 11.2%, EPS CAGR 3.6%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

· Insufficient peer data

Only 0 MoS peers in cohort

Value measures how the stock's price compares to its intrinsic worth. Higher means more discount to fair value.

Compare with another stock

Overlay ANTHEM's prism against a peer.

Share this prism

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for ANTHEM.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.

Anthem Biosciences Limited (ANTHEM) Prism — YieldIQ